| Literature DB >> 32623942 |
Athanasios Papadas1,2, Garrett Arauz1, Alexander Cicala1, Joshua Wiesner1, Fotis Asimakopoulos1.
Abstract
Versican is an extracellular matrix proteoglycan with key roles in multiple facets of cancer development, ranging from proliferative signaling, evasion of growth-suppressor pathways, regulation of cell death, promotion of neoangiogenesis, and tissue invasion and metastasis. Multiple lines of evidence implicate versican and its bioactive proteolytic fragments (matrikines) in the regulation of cancer inflammation and antitumor immune responses. The understanding of the dynamics of versican deposition/accumulation and its proteolytic turnover holds potential for the development of novel immune biomarkers as well as approaches to reset the immune thermostat of tumors, thus promoting efficacy of modern immunotherapies. This article summarizes work from several laboratories, including ours, on the role of this central matrix proteoglycan in tumor progression as well as tumor-immune cell cross-talk.Entities:
Keywords: biomarkers; dendritic cells; extracellular matrix; glycosaminoglycan; immunotherapy; macrophages; matrikines; myeloid cells; proteoglycan; versican; versikine
Mesh:
Substances:
Year: 2020 PMID: 32623942 PMCID: PMC7711242 DOI: 10.1369/0022155420937098
Source DB: PubMed Journal: J Histochem Cytochem ISSN: 0022-1554 Impact factor: 2.479